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OBJECTIVES We attempted to establish whether naloxone, an opioid receptor antagonist, abolishes the
adaptation to ischemia observed in humans during coronary angioplasty after repeated balloon
inflations.
BACKGROUND Experimental studies indicate that myocardial opioid receptors are involved in ischemic
preconditioning.
METHODS Twenty patients undergoing angioplasty for an isolated stenosis of a major epicardial coronary
artery were randomized to receive intravenous infusion of naloxone or placebo during the
procedure. Intracoronary electrocardiogram and cardiac pain (using a 100-mm visual analog
scale) were determined at the end of the first two balloon inflations. Average peak velocity in
the contralateral coronary artery during balloon occlusion, an index of collateral recruitment,
was also assessed by using a Doppler guide wire in the six patients of each group with a
stenosis on the left anterior descending coronary artery.
RESULTS In naloxone-treated patients, ST-segment changes and cardiac pain severity during the
second inflation were similar to those observed during the first inflation (12 6 6 vs. 11 6
7 mm, p 5 0.3, and 58 6 13 vs. 56 6 12 mm, p 5 0.3, respectively), whereas in
placebo-treated patients, they were significantly less (6 6 3 vs. 13 6 6 mm, p 5 0.002 and
31 6 21 vs. 55 6 22 mm, p 5 0.008, respectively). In both naloxone- and placebo-treated
patients, average peak velocity significantly increased from baseline to the end of the first
inflation (p 5 0.04 and p 5 0.02, respectively), but it did not show any further increase during
the second inflation.
CONCLUSIONS The adaptation to ischemia observed in humans after two sequential coronary balloon
inflations is abolished by naloxone and is independent of collateral recruitment. Thus, it is due
to ischemic preconditioning and is, at least partially, mediated by opioid receptors, suggesting
their presence in the human heart. (J Am Coll Cardiol 1999;33:1863–9) © 1999 by the
American College of Cardiology
Ischemic preconditioning, a powerful form of protection
against myocardial infarction (1), has been shown in several
animal species (1–4) and, more recently, in humans (5–10).
Several experimental studies have shown that precondition-
ing results from a complex series of events, involving various
G protein-coupled receptors (11,12). The stimulation of
these receptors would result in the activation of protein
kinase C (PKC). This, in turn, leads to the translocation of
PKC from the cytoplasm to the sarcolemma, where it
phosphorylates a substrate protein (possibly the adenosine
triphosphate–sensitive K1 [KATP] channel), which confers
resistance to ischemia (11,12). Recent studies have con-
firmed that A1-adenosine receptors (13,14), alpha-
adrenergic receptors (15) and KATP channels (16) play an
important role in mediating preconditioning also in hu-
mans.
The activation of opioid receptors has been shown to
trigger ischemic preconditioning in experimental models
(17–22). Indeed, their stimulation mimics and their block-
ade abolishes ischemic preconditioning in rat (17,18,20–22)
and rabbit (19) hearts. Of note, the mu- and delta-opioid
receptors are coupled to G proteins (23–25) and can activate
PKC in chicken neuron cultures (26) and KATP channels in
pig cerebral arteries (27) and in the rat heart (18). To
establish the role played by opioid receptors in precondi-
tioning in humans, we assessed the effects of naloxone (a
nonselective opioid receptor antagonist) (28) in patients
undergoing repeated coronary occlusions in the setting of
elective angioplasty of an isolated stenosis of a major
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epicardial coronary artery. Because collateral recruitment
can occur during coronary angioplasty (29,30), changes in
blood flow velocity in the contralateral coronary artery
during balloon occlusion (an accepted index of collateral
recruitment) (31–33), were also measured by using an
intracoronary Doppler guide wire.
METHODS
Patients. We studied 20 consecutive patients (17 men and
3 women; age range, 48 to 70 years; mean age, 60 years)
who underwent successful uncomplicated elective coronary
angioplasty for an isolated obstructive lesion (internal diam-
eter reduction of 50% to 90% on the basis of the use of the
quantitative cardiovascular software program ACA, Philips,
DCI, Best, The Netherlands.) (34) in the proximal two
thirds of a major epicardial coronary artery. Patients with
stenoses .90% were not included in the study, to avoid
“preinflation ischemia” due to obstruction from the guide
wire across the lesion, which would prolong the ischemic
time of the first inflation compared with the second (35).
All patients fulfilled the entry criteria of: 1) history of
chronic stable angina pectoris lasting $3 months; 2) no
history of previous myocardial infarction nor pathologic Q
waves on the electrocardiogram (ECG); 3) no angiographic
evidence of coronary collateral vessels (grade 0, according to
Rentrop’s classification) (29), and 4) right dominant coro-
nary circulation. No patient had evidence of left ventricular
hypertrophy or of wall motion abnormalities on the echo-
cardiogram or conduction defects on the ECG that could
have interfered with the interpretation of ST-segment
changes. All patients had normal hepatic and renal function
and fasting blood glucose levels. All patients gave written
informed consent for participation in the study, which was
approved by the Institutional Ethics Committee.
Study protocol. In this single-blind study, which was
performed within five days of the diagnostic coronary
angiography, patients were randomly allocated to two
groups. One group consisted of 10 patients (nine men and
one woman; age range, 48 to 68 years; mean age, 62 years)
who received an intravenous infusion of naloxone (naloxone
hydrochloride 0.4 mg/ml; DuPont Pharmaceuticals, Wil-
mington, Delaware). Naloxone was administered as a load-
ing dose (6-mg bolus over 5 min), followed by an intrave-
nous infusion at a rate of 0.1 mg/min. The infusion was
started 15 min before coronary angioplasty and was stopped
at the end of the second inflation. Naloxone was adminis-
tered at a dose previously shown to increase beta-endorphin
plasma levels, which indicates effective opiate receptor
blockade (36–38). The other group consisted of 10 patients
(8 men and 2 women; age range, 53 to 70 years; mean age,
59 years) who received an intravenous infusion of placebo
(6 ml of 0.9% NaCl as bolus over 5 min, followed by an
intravenous infusion at a rate of 1 ml/min), started 15 min
before coronary angioplasty and stopped at the end of the
second inflation. Beta-adrenergic blocking agents were
withdrawn five days before the study. All patients were on
oral aspirin (100 mg o.d.), diltiazem (60 mg t.i.d.) and
isosorbide dinitrate (40 mg b.i.d.) for $48 h before coronary
angioplasty. All patients received the morning dose of
treatment before coronary angioplasty, which was per-
formed within the next 4 h. No patient had angina in the
last 24 h before the study. No patient received sublingual or
intravenous nitrates in the last 24 h before the study or
throughout the study. Patients were not premedicated with
diazepam or other sedatives.
Coronary angioplasty of the stenosed artery was per-
formed by a standard technique using the right femoral
approach, as previously described (15,16). Briefly, after
placement of the guiding catheter through a 8-F femoral
sheath in the right femoral artery and performance of
baseline angiography, the guide wire was placed across the
lesion in the distal segment of the stenosed artery. The
balloon catheter was then placed within the stenosis, and
the balloon was inflated for 2 min. After balloon deflation
and withdrawal proximal to the lesion, with the guide wire
still across the lesion, a recovery period of $5 min was
allowed to reestablish baseline hemodynamic and ECG
conditions. A second balloon inflation for 2 min was then
performed. In each individual patient balloon pressure
during the first and second inflation was identical. After the
first two inflations, coronary angioplasty was completed on
the basis of the specific needs of individual patients.
Assessment of myocardial ischemia. Standard surface 12-
lead and intracoronary ECGs derived from the angioplasty
guide wire were continuously monitored and simultaneously
recorded (Mingograph 7, Siemens, Solna, Sweden) at a
paper speed of 25 mm/s throughout the study. The ECGs
were analyzed by a cardiologist who had no knowledge of
the study protocol. At baseline (with just the guide wire
across the lesion) and at the end of the first two inflations,
ST-segment shift was measured 80 ms after the J point. The
severity of myocardial ischemia was expressed as: 1) the
summation of the absolute values of the ST-segment
elevation or ST-segment depression from baseline, on
surface ECG, from all 12 leads; and 2) the absolute values
of the ST-segment elevation or ST-segment depression
from baseline on intracoronary ECG. ST-segment shifts
were expressed in millimeters (1 mm 5 0.1 mV).
Assessment of cardiac pain. At the beginning of each
coronary angioplasty procedure, patients were informed that
they might develop chest pain. At the end of the first two
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balloon inflations, the intensity of cardiac pain was assessed
by using a visual analog scale (39). Patients were asked to
put a mark on a 100-mm scale marked from no symptoms
(0) to severe symptoms (100). Time to pain onset (in
seconds) was also assessed.
Assessment of coronary blood flow velocity. In the six
patients of each group with a stenosis on the left anterior
descending coronary artery, a 5-F femoral sheath was also
inserted in the left femoral artery. A 5-F right Judkins
femoral catheter was advanced through the left femoral
sheath into the ostium of the right coronary artery for
guidance of a 0.014-in. (0.036 cm) Doppler-tipped guide
wire (FloWire, Cardiometrics, Mountain View, California).
After heparinization (10,000 U IV) and placement of the
angioplasty guiding catheter into the ostium of the left main
coronary artery and before administration of naloxone or
placebo infusion, a 0.014-in. Doppler-tipped intracoronary
guide wire (FloWire and FloMap, Cardiometrics) was
advanced through the 5-F right Judkins catheter into the
medium tract of the right coronary artery and positioned
until an optimal and stable Doppler signal, not in the
proximity of a side branch, was obtained. Blood flow
velocity was calculated as previously described (40,41).
Average peak velocity in the contralateral artery was mea-
sured at baseline, before the first (15 min after naloxone or
placebo infusion) and the second balloon inflations and at
the end of the first two inflations. Collateral recruitment
was expressed as the changes in average peak velocity in the
contralateral coronary artery during the first and second
balloon inflations.
Statistical analysis. Two-factor repeated measures analysis
of variance with repeated measures on one factor was used
to compare ischemic ECG and average peak velocity
changes during balloon inflations in the two groups of
patients. When significant differences were detected, pair-
wise comparisons were made using the Scheffe´ F test.
Comparisons of the remaining continuous or discrete vari-
ables between the two groups were performed using an
unpaired Student t or a chi-square test, respectively. Visual
analog scales were analyzed using the Wilcoxon signed rank
test or the Mann-Whitney U test as appropriate. Correla-
tions between changes in average peak velocity from the first
to the second inflation and changes in ST-segment shift
were assessed by univariate linear regression analysis. Data
are expressed as mean 6 1 SD; values of p , 0.05 were
considered significant.
RESULTS
There was no significant difference in clinical, anatomic or
hemodynamic features between the two groups (Table 1). In
both naloxone- and placebo-treated patients, the values of
systolic arterial pressure and heart rate were similar at
baseline, 15 min after naloxone or placebo infusion (imme-
diately before the first balloon inflation), before the second
balloon inflation and at the end of the first two inflations
(Table 1). During intravenous administration of naloxone as
a bolus, two patients complained of transient nausea not
associated with hemodynamic changes. No patient reported
any symptom during placebo infusion.
Coronary angioplasty was successfully performed in all 20
patients (residual stenosis ,30%) (Table 1). The mean
balloon pressure and the recovery period between the two
balloon inflations were similar in naloxone- and placebo-
treated patients (5.6 6 1.6 vs. 4.7 6 1.8 atm, p 5 0.3, and
361 6 69 vs. 392 6 61 s, p 5 0.3, respectively).
Myocardial ischemia. The values of ST-segment shift
from baseline at the end of the first two inflations are
reported in Table 2. In naloxone-treated patients, the mean
ST-segment shift at the end of the second balloon inflation
was similar to that at the end of the first inflation on both
the surface ECG (10 6 5 vs. 10 6 2 mm, p 5 0.9) and the
intracoronary ECG (12 6 6 vs. 11 6 7 mm, p 5 0.3).
Conversely, in placebo-treated patients, the mean ST-
segment shift at the end of the second balloon inflation was
significantly less than that at the end of the first inflation on
Table 1. Clinical, Anatomic and Hemodynamic Features in the
Two Groups of Patients
Naloxone
(n 5 10)
Placebo
(n 5 10)
p
Value
Age (yr) 62 6 6 59 6 6 0.3
Male/female (n) 9/1 8/2 1.0
Vessel disease (%)
LAD 60 60
LCx 10 20 0.8
RCA 30 20
Degree of stenosis (%)
Before PTCA 86 6 10 84 6 11 0.8
After PTCA 18 6 5* 16 6 6* 0.4
Heart rate (bpm)
Before infusion 69 6 14 73 6 12 0.5
15 min after infusion
(baseline 1)
69 6 10 74 6 13 0.4
Inflation 1 69 6 13 74 6 10 0.3
Baseline values
(baseline 2)
67 6 12 71 6 11 0.4
Inflation 2 68 6 13 73 6 9 0.3
Systolic arterial pressure
(mm Hg)
Before infusion 136 6 25 139 6 32 0.8
15 min after infusion
(baseline 1)
129 6 26 136 6 28 0.6
Inflation 1 128 6 20 128 6 20 1.0
Baseline values
(baseline 2)
136 6 22 135 6 23 1.0
Inflation 2 125 6 19 130 6 21 0.6
*p , 0.001 vs. stenosis before PTCA.
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; PTCA 5 percutaneous transluminal coronary angioplasty; RCA 5 right
coronary artery.
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both the surface ECG (6 6 3 vs. 11 6 6 mm, p 5 0.002)
and the intracoronary ECG (6 6 3 vs. 13 6 6 mm, p 5
0.002) (Fig. 1). The drug–inflation interaction for ST-
segment changes on the surface and the intracoronary
ECGs was highly significant (p 5 0.004 and p , 0.001,
respectively). There was no significant difference between
the two groups of patients in the degree of ST-segment shift
at the end of the first inflation on either surface (p 5 0.5) or
intracoronary ECG (p 5 0.6) (Table 2). Finally, in both
naloxone- and placebo-treated patients, changes in average
peak velocity from the first to the second inflation did not
correlate with those in ST-segment shift on surface (r 5
0.12, p 5 0.7, and r 5 0.22, p 5 0.6, respectively) or
intracoronary ECG (r 5 0.15, p 5 0.7, and r 5 0.11, p 5
0.8, respectively).
Cardiac pain. In naloxone-treated patients, the severity of
cardiac pain and time to pain onset at the end of the second
inflation were similar to those at the end of the first inflation
(58 6 13 vs. 56 6 12 mm, p 5 0.3, and 48 6 20 vs. 54 6
20 s, p 5 0.1, respectively). Conversely, in placebo-treated
patients, the severity of cardiac pain and time to pain onset
at the end of the second inflation were less and, respectively,
longer than those at the end of the first inflation (31 6 21
vs. 55 6 22 mm, p 5 0.008, and 65 6 22 vs. 56 6 31 s, p 5
0.02, respectively) (Fig. 1). There was no significant differ-
ence between the two groups of patients in cardiac pain
severity (p 5 0.9) or time to pain onset (p 5 0.9) at the end
of the first inflation (Table 2).
Coronary blood flow velocity. The values of average peak
velocity in the contralateral artery in the six patients of each
group with a stenosis on the left anterior descending
coronary artery are reported in Table 2.
In both naloxone- and placebo-treated patients, average
peak velocity in the right coronary artery significantly
increased from baseline to the end of the first inflation (from
22 6 7 to 26 6 6 cm/s, p 5 0.04, and from 21 6 6 to 25 6
6 cm/s, p 5 0.02, respectively), but it did not show a further
increase during the second inflation (27 6 6 and 26 6
7 cm/s, respectively; p 5 0.2 and p 5 0.1, vs. the first
inflation). There was no significant difference between the
two groups of patients in average peak velocity at the end of
the first (p 5 0.7) and the second inflation (p 5 0.7)
(Table 2).
DISCUSSION
Several previous studies carried out in vitro on human
myocardial tissue (5,6) and in patients undergoing coronary
artery bypass surgery (9) have consistently demonstrated
that ischemic preconditioning does occur in man. This
concept is further strengthened by the observation that
preinfarction angina is a powerful and independent predic-
tor of better short- and medium-term prognosis after acute
myocardial infarction (10). Our results, in agreement with
those of previous studies based on the same model (7,8,13–
16), confirm that ischemic preconditioning also occurs in
humans during repeated balloon inflations in the setting of
coronary angioplasty. More important, our study indicates
Table 2. Values of ST-Segment Shift, Cardiac Pain and Average Peak Velocity in the
Contralateral Coronary Artery in the Two Groups of Patients
Naloxone
(n 5 10)
Placebo
(n 5 10)
p
Value
ST-segment shift on S-ECG (mm)*
Inflation 1 10 6 2 11 6 6 0.5
Inflation 2 10 6 5 6 6 3† 0.05
ST-segment shift on IC-ECG (mm)*
Inflation 1 11 6 7 13 6 6 0.6
Inflation 2 12 6 6 6 6 3† 0.01
Pain severity (mm)*
Inflation 1 56 6 12 55 6 22 0.9
Inflation 2 58 6 13 31 6 21† 0.009
Time to pain onset(s)*
Inflation 1 54 6 20 56 6 31 0.9
Inflation 2 48 6 20 65 6 22‡ 0.08
Average peak velocity in the RCA (cm/s)
Before infusion 22 6 7 21 6 6 0.8
15 min after infusion (baseline 1) 22 6 7 21 6 6 0.8
Inflation 1 26 6 6§ 25 6 6§ 0.7
Baseline values (baseline 2) 23 6 6 21 6 6 0.5
Inflation 2 27 6 6§ 26 6 7§ 0.7
*Drug–inflation interaction statistically significant (p , 0.05). †p , 0.01 vs. inflation 1 value. ‡p , 0.05 vs. inflation 1 value.
§p , 0.05 vs. baseline 1 and baseline 2 values. Values of average peak velocity refer to the six patients of each group with a
stenosis on the left anterior descending coronary artery.
IC-ECG 5 intracoronary electrocardiogram; RCA 5 right coronary artery; S-ECG 5 surface 12-lead ECG.
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that opioid receptors are present in the human heart and
that they play an important role in ischemic precondition-
ing. Indeed, the latter was prevented by pretreatment with
naloxone, a powerful nonselective antagonist of opioid
receptors (28).
The statistical power of the study in the assessment of
ST-segment changes in naloxone-treated patients was suf-
ficiently high (.90% for pairwise comparisons). Thus,
although the number of patients was small, it is unlikely that
significant changes in ST-segment shift during the first and
second inflation were not detected.
Role of opioid receptors in ischemic preconditioning.
Schultz et al. (17) were the first to demonstrate that opioid
receptors are involved in the signaling pathway of ischemic
preconditioning, using naloxone, the nonselective opioid
receptor antagonist, in the intact rat heart. Subsequently,
Chien and Van Winkle (19) have demonstrated that opioid
receptors are also involved in ischemic preconditioning in
the rabbit heart and that naloxone blockade of ischemic
preconditioning-induced infarct size limitation is stereospe-
cific and, therefore, is opioid receptor–mediated. More
recently, Gross and his coworkers have also shown that
ischemic preconditioning in the intact rat heart is mediated
by delta1- but not mu- or kappa-opioid receptors (22). In
agreement with experimental studies (17–22), our results
indicate that pretreatment with naloxone abolishes ischemic
preconditioning in patients undergoing coronary angio-
plasty, a finding consistent with the concept that the
endogenous opioid system mediates ischemic precondition-
ing also in humans. Our findings are supported by the early
results by Bolli’s group (42), who found that pretreatment
with morphine sulphate mimics ischemic preconditioning
during coronary angioplasty.
As naloxone has been shown to cross the blood–brain
barrier thus having the capability of antagonizing both
central and peripheral opioid receptors (28,43), our study
does not provide any direct evidence whether the prevention
of preconditioning during coronary angioplasty was of a
central or peripheral origin. However, it seems unlikely that
our results are due to a central opioid receptor blockade by
naloxone, because the infusion of naloxone did not change
heart rate, blood pressure or coronary blood flow. Thus, it is
likely that, in our study, naloxone prevented precondition-
ing during repeated coronary occlusions through the block-
ade of a peripheral opioid receptor mechanism. This is in
agreement with a recent study by Gross and his coworkers
(20), in which the involvement of central or peripheral
opioid receptor pathways in ischemic preconditioning in the
intact rat heart has been addressed. To this end, they
compared the effect of naloxone to that of its quaternary
derivative with a positively charged nitrogen, naloxone
methiodide, which has been shown not to cross the blood–
brain barrier (44,45). They found that naloxone methiodide
like naloxone, abolished the infarct limitation of ischemic
preconditioning, thus suggesting a peripheral involvement
of opioid receptors in myocardial protection (20).
At the present time, the mechanism by which opioid
receptors produce their cardioprotective actions is not clear
and cannot be deduced by the results of the present study. It
is known that mu- and delta-opioid receptors are coupled to
G proteins (23–25) and can activate KATP channels in
regulating antinociception (46–49) and cerebral vascular
control (27). It is worth noting that glibenclamide has been
recently shown to abolish morphine-induced cardioprotec-
tion in the rat heart, thus suggesting an involvement of the
myocardial KATP channel as an important component of
this cardioprotective effect (18). As KATP channels have
been previously shown to be involved in ischemic precon-
ditioning during coronary angioplasty (16), opioid receptor-
induced cardioprotection is probably mediated via KATP
channel also in the human heart.
In the present study, naloxone infusion did not affect
cardiac pain during the first coronary balloon occlusion.
These findings are in agreement with the results of several
previous studies (36,50,51) and, in particular, with those of
Marchant et al. (36), who failed to modify the time to onset
of angina during exercise test at a dose of naloxone identical
Figure 1. Values of ST-segment shifts on the intracoronary
electrocardiogram (IC-ECG) and of cardiac pain severity at the
end of the first and second balloon inflations in the two groups of
patients. In naloxone-treated patients, ST-segment changes and
cardiac pain severity at the end of the second balloon inflation were
similar to those at the end of the first inflation. Conversely, in
placebo-treated patients, ST-segment changes and cardiac pain
severity at the end of the second balloon inflation were significantly
less than those at the end of the first inflation.
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to that used in our study. The inability of naloxone to affect
the severity of angina might suggest that endogenous
opiates do not play a major role in the modulation of cardiac
ischemic pain. Alternatively, it is possible that in the central
nervous system naloxone did not reach adequate concentra-
tions at the site of opioid receptors potentially able to affect
angina severity.
Limitation of the angioplasty model of preconditioning.
There are three major concerns with the angioplasty model
of preconditioning: 1) the adaptation to ischemia observed
after repeated coronary balloon occlusions might be due to
progressive collateral recruitment, rather than to a metabolic
myocardial adaptation, that is, ischemic preconditioning; 2)
the electrocardiographic changes might not reflect a precon-
ditioning state, and 3) patients might have experienced
silent ischemia in the 24 h before the study. With regard to
the first point, we assessed changes in blood flow velocity in
the contralateral coronary artery during balloon occlusion by
using a Doppler guide wire. In the absence of significant
changes in arterial pressure or heart rate, as was the case in
our study at the end of both inflations, blood flow velocity
changes in the contralateral coronary artery have been
shown to be a reliable index of collateral perfusion and
function during coronary angioplasty, more accurate than
thermodilution, measurement of coronary occlusion pres-
sure through the balloon catheter or angiographic visualiza-
tion of collateral vessels (31–33). We found that coronary
blood flow velocity significantly increased at the end of the
first inflation in both groups of patients, whereas it did not
exhibit any further increase during the second inflation.
These findings confirm our previous results (15) and are in
agreement with those of Kyriakidis et al. (33) and Cribier et
al. (52). We measured right-to-left collateral recruitment
only, thus probably underestimating total collateral flow.
However, intracoronary collateral recruitment is unlikely to
explain the adaptation to ischemia observed in our study for
two reasons. First, patients were randomized to placebo and
naloxone and, therefore, it is unlikely that contribution of
intracoronary collateral recruitment was different in
placebo- and naloxone-treated patients. Second, to the best
of our knowledge, naloxone does not influence collateral
flow.
With regard to the second point, Shattock et al. (53),
who measured ST-segment changes in open-chest pigs,
subjected to two cycles of 8-min ischemia and 8-min
reperfusion followed by 60-min ischemia and 2-h reperfu-
sion, found that ST-segment changes provide a reliable
index of preconditioning during the first few minutes of
coronary occlusion. More recently, Cohen et al. (54) have
shown that pharmacologic induction or blockade of protec-
tion altered the electrocardiographic response accordingly,
suggesting that the attenuation of ST-segment changes
during repetitive coronary occlusions truly reflects the pro-
tection of ischemic preconditioning and is not merely an
epiphenomenon.
With regard to the third point, an episode of silent
ischemia in the last 24 h before the study cannot be ruled
out; however, as patients were randomized to placebo and
naloxone, possible episode of silent ischemia should, in
theory, be equally distributed between groups.
Clinical implications. The experimental and clinical find-
ings showing that opioid receptors are involved in ischemic
preconditioning suggest that opioid agonists may possess,
aside from their specific analgesic and anesthetic effects, a
previously unrecognized beneficial cardioprotective effect in
the clinical setting. A better knowledge of the specific
opioid receptor subtypes involved in ischemic precondition-
ing might allow the development of new opioid agonists
with specific cardioprotective properties and without any
potential adverse effects on central nervous system or cardiac
contractility.
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